1.27  1.27 (-7.3%)		04-20 16:00
Open: 1.235 High: 1.41 Volume: 1,691,206		Pre. Close: 1.27 Low: 1.231 Market Cap: 7(M)

Short term
Mid term
Targets	6-month :	3.12	1-year :	4.48
Resists	First :	2.67	Second :	3.83
Pivot price	1.25
Supports	First :	0.8	Second :	0.66
MAs	MA(5) :	1.29	MA(20) :	1.18
	MA(100) :	15.6	MA(250) :	15.43
MACD	MACD :	-0.4	Signal :	-0.6
%K %D	K(14,3) :	15.8	D(3) :	15.1
RSI	RSI(14): 42
52-week	High :	45.5	Low :	0.8

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ QNCX ] has closed below upper band by 46.7%. Bollinger Bands are 93.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 41 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.41 - 1.42	1.42 - 1.43
Low:	1.21 - 1.22	1.22 - 1.23
Close:	1.28 - 1.29	1.29 - 1.3

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Sat, 18 Apr 2026
QNCX Sees Increased Price Target Amidst Maintained Buy Rating | - GuruFocus

Sat, 18 Apr 2026
symbol__ Stock Quote Price and Forecast - CNN

Thu, 09 Apr 2026
Quince Therapeutics (QNCX) enacts 1-for-10 reverse split, 16.3M shares post-split - Stock Titan

Thu, 09 Apr 2026
Quince Therapeutics to implement 1-for-10 reverse stock split effective Friday - Investing.com

Wed, 01 Apr 2026
Quince Therapeutics (QNCX) delays 2025 10-K after failed Phase 3; seeks 15-day extension - Stock Titan

Mon, 30 Mar 2026
Quince Therapeutics settles $16.4M debt with $5.5M payment - MSN

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	16 (M)
Shares Float	15 (M)
Held by Insiders	3.1 (%)
Held by Institutions	13.4 (%)
Shares Short	1,380 (K)
Shares Short P.Month	830 (K)

EPS	-16.8
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-6.41
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-30.4 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.09
Qtrly Earnings Growth	0 %
Operating Cash Flow	-41 (M)
Levered Free Cash Flow	-11 (M)

PE Ratio	-0.08
PEG Ratio	0
Price to Book value	-0.21
Price to Sales	0
Price to Cash Flow	-0.51

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.